These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 7076630

  • 1. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
    Odejide OA, Aderounmu AF.
    J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
    [Abstract] [Full Text] [Related]

  • 2. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
    Wistedt B.
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():15-23. PubMed ID: 3549878
    [Abstract] [Full Text] [Related]

  • 3. Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.
    Wistedt B, Palmstierna T.
    J Clin Psychiatry; 1983 Oct; 44(10):369-71. PubMed ID: 6643398
    [Abstract] [Full Text] [Related]

  • 4. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K.
    Acta Psychiatr Belg; 1982 Oct; 82(2):216-23. PubMed ID: 7180558
    [Abstract] [Full Text] [Related]

  • 5. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G, Annable L, Campbell W.
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [Abstract] [Full Text] [Related]

  • 6. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
    Cookson JC, Kennedy NM, Gribbon D.
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():41-51. PubMed ID: 3549879
    [Abstract] [Full Text] [Related]

  • 7. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
    Inderbitzin LB, Lewine RR, Scheller-Gilkey G, Swofford CD, Egan GJ, Gloersen BA, Vidanagama BP, Waternaux C.
    Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
    [Abstract] [Full Text] [Related]

  • 8. A long term comparative trial of penfluridol and fluphenazine decanoate in schizophrenic outpatients.
    Iqbal MJ, Young MA, Charles J, Elgart B, Von Greiff H, Simpson GM.
    J Clin Psychiatry; 1978 Apr; 39(4):375-9. PubMed ID: 580285
    [Abstract] [Full Text] [Related]

  • 9. The dysphoric syndrome in schizophrenia and its implications for relapse.
    Hirsch SR, Jolley AG.
    Br J Psychiatry Suppl; 1989 Jul; (5):46-50. PubMed ID: 2690890
    [No Abstract] [Full Text] [Related]

  • 10. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
    Kissling W, Möller HJ, Walter K, Wittmann B, Krueger R, Trenk D.
    Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
    [Abstract] [Full Text] [Related]

  • 11. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients.
    Walker CA.
    Pharmatherapeutica; 1983 May; 3(5):289-93. PubMed ID: 6133287
    [Abstract] [Full Text] [Related]

  • 12. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
    Kong DS, Yeo SH.
    Pharmatherapeutica; 1989 May; 5(6):371-9. PubMed ID: 2687894
    [Abstract] [Full Text] [Related]

  • 13. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
    Jayaram G, Coyle J, Tune L.
    J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
    [Abstract] [Full Text] [Related]

  • 14. Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study.
    Litman RE, Hong WW, Weissman EM, Su TP, Potter WZ, Pickar D.
    J Clin Psychopharmacol; 1993 Aug; 13(4):264-7. PubMed ID: 8104200
    [Abstract] [Full Text] [Related]

  • 15. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
    Altamura AC, Mauri MC, Girardi T, Panetta B.
    Int J Clin Pharmacol Res; 1990 Aug; 10(4):223-8. PubMed ID: 2079381
    [Abstract] [Full Text] [Related]

  • 16. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia.
    Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J.
    Arch Gen Psychiatry; 1982 Jan; 39(1):70-3. PubMed ID: 6275811
    [Abstract] [Full Text] [Related]

  • 17. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia.
    Leong OK, Wong KE, Tay WK, Gill RC.
    Singapore Med J; 1989 Oct; 30(5):436-40. PubMed ID: 2575796
    [Abstract] [Full Text] [Related]

  • 18. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G, Annable L, Ross-Chouinard A.
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract] [Full Text] [Related]

  • 19. Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates.
    McLaren S, Cookson JC, Silverstone T.
    Int Clin Psychopharmacol; 1992 Nov; 7(2):67-72. PubMed ID: 1487623
    [Abstract] [Full Text] [Related]

  • 20. A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse.
    Steingard S, Allen M, Schooler NR.
    J Clin Psychiatry; 1994 Nov; 55(11):470-2. PubMed ID: 7989278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.